ImmunityBio Shares Surge 7.29% on $260M Trading Volume Ranking 454th as Scalable NK-Cell Therapy Validation and Phase 1 Trial Safety Data Drive Investor Optimism

Market Snapshot

ImmunityBio (NASDAQ: IBRX) surged 7.29% on March 13, 2026, with a trading volume of $0.26 billion, a 121.33% increase from the prior day, ranking it 454th in market activity. The stock’s performance followed the company’s announcement of completed manufacturing engineering programs (NK2022 and NK2023) for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. These programs validated a scalable, reproducible pathway for large-volume leukapheresis and downstream NK cell enrichment, enabling the production of up to 5 billion highly pure M-ceNK cells per apheresis—yielding 8–10 therapeutic doses within 12 days. The results, coupled with a Phase 1 trial (QUILT-3.076) demonstrating the safety of combining M-ceNK with ANKTIVA® in relapsed/refractory tumors, fueled investor optimism.

Key Drivers

Manufacturing Validation and Scalability

ImmunityBio’s NK2022 and NK2023 programs enrolled 64 subjects (healthy donors and cancer patients) to test the safety and reproducibility of its M-ceNK cell production process. All participants completed apheresis without serious adverse events, and 10 cancer patients received their enriched M-ceNK cells, with 23 total doses administered. The ability to generate up to 5 billion M-ceNK cells per apheresis, cryopreserved with retained cytotoxicity against tumor cell lines, marked a critical milestone. CEO Patrick Soon-Shiong emphasized the potential to create a “World Bank of NK Cells,” enabling universal, HLA-matching-free donations. This scalability addresses a key challenge in cell therapy, where production complexity and cost often limit accessibility.

Phase 1 Trial Safety and Antitumor Efficacy

The QUILT-3.076 trial, combining M-ceNK with ANKTIVA® (nogapendekin alfa inbakicept-pmln), demonstrated favorable safety in 10 patients with relapsed/refractory solid tumors. Weekly M-ceNK infusions (0.25–0.75×10⁹ cells) and biweekly ANKTIVA® subcutaneous doses resulted in zero Grade 4/5 treatment-related adverse events or cytokine storms. The combination leverages ANKTIVA’s IL-15 superagonist activity to sustain M-ceNK proliferation, enhancing antitumor persistence. Preclinical data from the National Cancer Institute further supported the platform, showing tumor volume reductions in SCLC xenograft models and increased MHC-Class I expression on residual tumors, suggesting a dual mechanism of direct NK cell killing and immune checkpoint inhibitor (ICI) sensitization.

Strategic Automation and Global Access

ImmunityBio highlighted its readiness to implement AI-driven robotic systems (NANT Leonardo) for M-ceNK manufacturing, streamlining production and reducing variability. The company’s cryopreservation process, validated across 64 subjects, ensures long-term storage of M-ceNK cells without compromising efficacy. This infrastructure positions ImmunityBio to expand access to NK cell therapies, particularly for neuroendocrine tumors, where 62% of cases lack MHC-Class I expression and are resistant to T cell-based immunotherapies. By generating high-purity, activating receptor-rich M-ceNK cells with potent cytotoxicity against diverse tumor models, the platform addresses a significant unmet need in oncology.

Market Implications and Analyst Sentiment

The stock’s surge reflects investor confidence in ImmunityBio’s progress toward commercializing its Cancer BioShield™ platform, anchored by ANKTIVA and M-ceNK therapies. Analysts at BTIG and Piper Sandler have reiterated Buy ratings, citing the FDA resubmission for ANKTIVA in BCG-unresponsive bladder cancer and the potential for global NMIBC expansion. The company’s focus on reducing reliance on high-dose chemo-radiation therapy and its pipeline of allogeneic NK-cell therapies further underscore its strategic differentiation. However, risks remain, including regulatory hurdles, manufacturing scale-up challenges, and competition from emerging immunotherapies.

Forward-Looking Considerations

While the recent data strengthens ImmunityBio’s clinical and manufacturing credibility, long-term success will depend on confirmatory Phase 2/3 trials, regulatory approvals, and scalable commercialization. The integration of AI-driven automation and the “World Bank of NK Cells” concept, if realized, could redefine cell therapy accessibility. Investors remain cautiously optimistic, balancing the company’s innovative pipeline with the inherent risks of biotech development. For now, the successful validation of M-ceNK production and the safety profile of its combination therapies have solidified ImmunityBio’s position as a key player in the evolving immunotherapy landscape.